Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Common Equity: 2015-2025

Historic Common Equity for Spyre Therapeutics (SYRE) over the last 10 years, with Sep 2025 value amounting to $455.1 million.

  • Spyre Therapeutics' Common Equity rose 39.01% to $455.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $455.1 million, marking a year-over-year increase of 39.01%. This contributed to the annual value of $517.8 million for FY2024, which is 181.39% up from last year.
  • Spyre Therapeutics' Common Equity amounted to $455.1 million in Q3 2025, which was down 0.15% from $455.8 million recorded in Q2 2025.
  • Spyre Therapeutics' 5-year Common Equity high stood at $517.8 million for Q4 2024, and its period low was -$245.4 million during Q3 2023.
  • In the last 3 years, Spyre Therapeutics' Common Equity had a median value of $327.4 million in 2024 and averaged $230.0 million.
  • Per our database at Business Quant, Spyre Therapeutics' Common Equity crashed by 463.26% in 2023 and then spiked by 352.48% in 2024.
  • Over the past 5 years, Spyre Therapeutics' Common Equity (Quarterly) stood at $83.9 million in 2021, then crashed by 40.07% to $50.3 million in 2022, then soared by 265.80% to $184.0 million in 2023, then spiked by 181.39% to $517.8 million in 2024, then surged by 39.01% to $455.1 million in 2025.
  • Its Common Equity was $455.1 million in Q3 2025, compared to $455.8 million in Q2 2025 and $482.6 million in Q1 2025.